DOL’s Final PBM Fee Disclosure Rule

Since 2025, the U.S. Department of Labor (DOL) has pushed for more transparency into how pharmacy benefit managers (PBMs) are paid, whether directly by health plans or indirectly through drugmakers and pharmacies. On Feb. 3, 2026, the Consolidated Appropriations Act of 2026 (CAA, 2026) was signed into law. The funding package includes a broad range of healthcare provisions, including significant reforms to the PBM industry. Separately, on Oct. 29, 2026, the DOL issued a final rule establishing new PBM fee disclosure obligations, further underscoring the federal government’s increasing focus on regulating the industry.
 
PBMs are third parties that manage most health plans’ prescription drug benefits. Health plans generally rely on PBMs to process prescription drug claims, design pharmacy networks and negotiate rebates from drug manufacturers. In recent years, the PBM industry has faced growing scrutiny amid questions from stakeholders regarding a lack of PBM transparency and certain PBM practices, such as retaining a share of drug manufacturer rebates and the use of spread pricing. In response, state PBM laws have surged nationwide in the absence of federal regulations.
 
This article highlights the key takeaways from the DOL’s final PBM Fee Disclosure rule and what self-insured employers should know before it applies to plan years beginning on or after July 1, 2027.

Transparency for Large Self-insured Plans

The final rule applies to large self-insured health plans subject to the Employee Retirement Income Security Act (ERISA), including those sponsored by employers with 100 or more participants. Large self-insured limited-scope plans, such as dental and vision, are also covered. The rule applies to plan years beginning on or after July 1, 2027, which, for calendar-year plans, means Jan. 1, 2028.
 
Although the final rule excludes fully insured group health plans, the DOL stated that it is reserving more detailed regulatory disclosure obligations for these plans for future action. In the meantime, PBMs contracting with insurers must still satisfy ERISA’s disclosure requirements to rely on the prohibited transaction exemption.
 
The rule does not specifically address individual coverage health reimbursement arrangements (ICHRAs), also known as CHOICE Arrangements, although plans outside its scope may still have disclosure rights under other laws.
 
Under the final rule, PBMs must disclose manufacturer rebates and other payments, spread pricing arrangements, pharmacy recoupments and other compensation, including payments from pharmacies tied to a plan’s prescription drug claims. Disclosures must also explain formulary-related incentives and key aspects of drug pricing. The requirements apply to PBMs, including PBM-affiliated brokers and consultants.

Expanded Access to PBM Data and Audits

Large self-insured employers have been able to negotiate audit and reporting terms into their PBM contracts, but how much they could see depended on what the contract said. Many reported trouble getting complete information on manufacturer rebates, spread pricing and other PBM compensation.
 
The gap matters more as drug spending takes up a larger share of employers’ health budgets. Segal projects a prescription drug trend of 11.5% for 2027, driven by specialty drugs and the growing use of glucagon-like peptide-1 (GLP-1) medications. KFF found that just under half of large employers report getting enough insight into what drugmakers pay their health plan or PBM. The rule sets clearer reporting and audit standards, enabling employers to evaluate PBM arrangements and understand what is driving their drug costs.
 
Under the final rule, covered plans receive reports every six months and can request them quarterly. For contract extensions and renewals, disclosure at least 90 days in advance is treated as reasonable. Plans can choose their own auditor and get the records needed to verify the disclosures, which providers generally must supply within 60 calendar days. Plans may audit at least once a year, and the PBM must acknowledge an audit request within 10 business days. Employers can use those records to check for themselves how prescription drug dollars move through the supply chain.

Rule Limits and Remaining Questions

Two federal frameworks now address PBM transparency: the Consolidated Appropriations Act (CAA) of 2026 and the DOL’s rule. In the department’s view, the CAA primarily provides retrospective information on prescription drug spending and use, whereas the new rule provides employers with upfront information when evaluating PBM contracts and renewals. The DOL aligned many of the rule’s definitions, terminology and reporting timelines with the CAA.
 
PBM industry groups and the DOL disagree on whether a separate disclosure framework is needed. The industry groups, including the Pharmaceutical Care Management Association, argue that the rule overlaps with the CAA and adds administrative burden, especially for smaller PBMs. However, the DOL says the two serve different purposes. The CAA data looks back, and the rule helps plans compare PBMs before they sign.
 
The DOL rule requires disclosure but does not regulate how PBMs structure their compensation. It does not ban spread pricing or require every rebate to be passed through to health plans. The CAA, by contrast, will require PBMs to pass through 100% of all rebates, fees, alternative discounts and other remuneration to group health plans, for contracts entered into, renewed or extended entered for plan years beginning on or after Aug. 3, 2028. Better information does not guarantee lower costs or a better PBM arrangement. The definition of a PBM also remains unsettled at the edges. Entities that only process claims, handle appeals or provide pharmacy compliance services may fall outside it, and the DOL did not clearly state whether the reporting duties extend to other vendors serving large self-insured plans. The department has said it will consider requests for further guidance after the rule is published.

CAA, 2026 Highlights

The CAA, 2026 includes comprehensive PBM industry reforms. Key highlights for health plan sponsors and health insurance issuers include the following:

PBMs must provide group health plans and health insurance issuers detailed prescription drug spending data at least twice per year, or quarterly if requested. PBMs must also supply drug spending summary documents that plans can share with participants and beneficiaries upon request.

Each year, group health plans must provide participants and beneficiaries with a written notice explaining that their PBM is required to submit prescription drug spending reports. This notice may be incorporated in plan documents or provided separately to individuals. Upon request, plans must also furnish:
 
  • The PBM’s summary document; and
  • For large plans, information showing the difference between what the plan paid the PBM and what the PBM paid the pharmacy for a covered drug associated with the requesting participant or beneficiary’s claim.

Failure to provide the required information by a PBM or group health plan may result in a civil monetary penalty of $10,000 for each day the information is not reported. Additional penalties may apply if false information is provided. Penalties may be waived for good-faith efforts to comply.

In order for their contracts to be considered reasonable under the Employee Retirement Income Security Act (ERISA) compensation disclosure rules, PBMs must pass on 100% of all rebates, fees, alternative discounts and other remuneration to group health plans and issuers. These rebates, fees and alternative discounts must generally be paid on a quarterly basis, fully disclosed and enumerated to the group health plan or issuer, and returned to the PBM if an audit by a plan sponsor, issuer or designated third party indicates overpayment to the plan. If a PBM fails to remit required rebates, plan fiduciaries will not be treated as violating ERISA as long as they satisfy certain requirements.
 
In addition, the bill expands ERISA’s “covered service provider” definition specifically to encompass PBM services, along with other health plan related services. ERISA requires covered service providers to disclose specified information about their services and all expected direct and indirect compensation to ensure plan fiduciaries have the information necessary to evaluate the reasonableness of service contracts.
In addition, the bill contains several Medicare Part D-related reforms, including:
 
  • Prohibiting PBM compensation in Medicare Part D from being tied to the manufacturer’s list price of a drug;
  • Requiring the Centers for Medicare & Medicaid Services (CMS) to define and enforce “reasonable and relevant” Medicare Part D contract terms, including reimbursement and dispensing fee information, with enforcement authority to impose monetary penalties; and
  • Authorizing CMS to track pharmacy payment trends and pharmacy inclusion in PBM networks, including a designation of “essential retail pharmacies.”

DOL Final Rule

Similar to the CAA, 2026, the DOL’s final rule significantly expands PBM disclosure obligations under ERISA’s compensation disclosure provisions by implementing an April 2025 Executive Order aimed at improving employer health plan transparency regarding PBM compensation.
 

Specifically, PBMs (including PBM-affiliated brokers and consultants) are required to provide initial and ongoing compensation disclosures to fiduciaries of large, ERISA-covered self-insured group health plans (generally those with 100 or more participants). The disclosures will enable these fiduciaries to assess the reasonableness of PBM compensation as part of their ERISA fiduciary duties. The final rule also allows plan fiduciaries to audit the accuracy of PBM disclosures.

Written initial disclosures to plan fiduciaries must be provided reasonably ahead of entering into, extending or renewing service contracts or arrangements. For renewals and extensions, providing the initial disclosure at least 90 days in advance is considered reasonable. Initial disclosures must include a description of:
 
  • Services: The PBM services, advice, recommendations, or referrals they will deliver under the contract or arrangement;
  • Direct compensation: The amount of compensation the PBM reasonably expects to receive directly from the plan or plan sponsor, by service and in total, including the amount allocated to each service in a bundled arrangement;
  • Indirect compensation: The amount of compensation the PBM reasonably expects to receive from sources other than the plan or plan sponsor for prescription drug claims during the disclosure period, including manufacturer payments, spread compensation, pharmacy recoupment and price protection agreements;
  • Compensation for termination: Any expected compensation related to contract termination, including how prepaid amounts are calculated and refunded;
  • Other compensation: Any compensation not already disclosed, including the payer, services involved and a description of the arrangement;    
  • Formulary placement incentives: Incentives or arrangements with manufacturers that affect drug placement on formularies and their impact on the plan and participant;    
  • Drug pricing methodology: The net price that will be paid for drugs after rebates and fees, or the methodology used to determine the net price if a monetary amount cannot be determined;    
  • Statement of fiduciary status: If applicable, a statement that the PBM expects to act as a fiduciary with respect to the plan; and
  • Statement of audit rights: A statement explaining the plan’s right to audit the CSP’s disclosures and procedures for requesting an audit.

PBMs must also provide ongoing disclosures on a semiannual basis, or quarterly if the group health plan requests. These disclosures generally include the same categories of compensation as the initial disclosures. According to the DOL, this allows a fiduciary to compare actual compensation with the amounts originally disclosed and monitor the arrangement over time, which helps the fiduciary determine whether the PBM’s compensation remains reasonable.

For each semiannual period, or each quarter if requested by the plan, the PBM must disclose the actual amounts received or reasonably expected to be received for direct compensation, manufacturer payments, spread compensation, pharmacy recoupment, price protection agreements, and any other compensation not covered in these categories. PBMs must also provide a compensation overage explanation if an amount reported in an ongoing disclosure exceeds the amount in the initial disclosure by 5 percent or more (or a lower threshold as agreed to by the parties). The overage explanation must identify the amount of the overage and explain the reason for it. 

The final rule grants group health plans audit rights to help plan fiduciaries monitor PBMs. Specifically, a group health plan may audit a PBM at least once a year to verify accuracy of its disclosures. The plan has the right to independently choose its auditor, and PBMs may not restrict that choice or limit the timing or location of the audit, or access to information needed for it. PBMs must acknowledge an audit request within 10 business days and generally must provide the necessary information within 60 calendar days. 

Recognizing that PBMs may sometimes fail to meet their disclosure obligations, the final rule provides an additional administrative exemption for responsible plan fiduciaries when a PBM fails to comply. To rely on the exemption, fiduciaries must take certain steps, including notifying the DOL if the PBM does not correct the failure.

Employer Takeaways

To prepare for the DOL’s final rule, plan sponsors of large self-insured health plans can take these steps:
 
  • Confirm whether the plan is covered and when the first covered plan year begins.
  • Review the PBM contract’s renewal date, audit rights and reporting terms.
  • Ask the PBM now what it will report, in what format and on what schedule, and raise those points in the next renewal discussion.
  • Work out how the new disclosures will fit with the reporting required under the CAA beginning with plan years on or after Aug. 3, 2028.
  • Decide now who will review the reports, whether that is the consultant, counsel or an internal team and how to document that review. Then compare those findings against the plan’s cost goals and participants’ needs.

Conclusion

The DOL’s final PBM fee disclosure rule gives large self-insured employers a clearer view of PBM compensation and stronger audit rights. Disclosure alone doesn’t show whether an arrangement delivers value. Rebates, spread pricing, formulary incentives and other compensation data give a fuller picture of how a drug program operates, but someone has to read and act on them.
 
The DOL is applying a temporary enforcement policy from Feb. 3, 2026, until the rule’s requirements apply, while parties develop ways to comply. That leaves time to prepare, though less if your PBM contract renews before the requirements apply.
 
Contact us to discuss what the rule means for your plan and how to use the disclosures in PBM contracting and negotiation.

This article is not intended to be exhaustive nor should any discussion or opinions be construed as professional or legal advice. Readers should contact legal counsel for legal advice. © 2026 Zywave, Inc. All rights reserved.

Author